PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

 

Dallas, TX -- February 26, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research which initiated analyst coverage in October last year and published a first update in November of last year confirming a Speculative Buy and $0.25 Target PPS.  The company has since the first update signed additional contracts and launched an all new formulation and packaging of its EVERx CBD Sports Water.  Earlier today, the company previewed a major coming announcement regarding its EVERx CBD Sports Water planned for release later this week. The previewed announcement expected later this week is separate from the Analyst Report update planned for release on Thursday this week.  The update report is anticipated to include an assessment of PURA’s $1.5 million contract with Generex Biotechnology (USOTC: GNBT) to produce custom, private ladled, CBD Infused water for Generex.  PURA is working with Kali-Extracts (USOTC: KALY) to develop the customer CBD extract formulation for infusion into the water produced for Generex.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,
[e-mail]
[phone]